What do systematic reviews say?

Low molecular weight heparin vs UFH

LMWH showed no clear difference in overall mortality (end of compared with UFH (moderate certainty).

• Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial… 2017 · Cochrane Headline outcomes only
  OR 0.84 [0.7, 1.01]
  24 studies · 9663 participants
  Moderate

Low molecular weight heparin vs vitamin K antagonist (VKA)

LMWH showed no clear difference in incidence of recurrent VTE (treatment duration 3 months) compared with VKA (moderate certainty).

• Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous… 2017 · Cochrane Headline outcomes only
  Peto OR 0.83 [0.6, 1.15]
  16 studies · 3299 participants
  Moderate

Low molecular weight heparin vs vitamin K antagonist (VKA)

LMWH may leads to lower incidence of major bleeding (treatment duration 3 months) compared with VKA (low certainty).

• Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous… 2017 · Cochrane Headline outcomes only
  Peto OR 0.51 [0.32, 0.8]
  16 studies · 3299 participants
  Low

Low molecular weight heparin vs vitamin K antagonist (VKA)

LMWH showed no clear difference in mortality (treatment duration 3 months) compared with VKA (moderate certainty).

• Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous… 2017 · Cochrane Headline outcomes only
  Peto OR 1.08 [0.75, 1.56]
  16 studies · 3299 participants
  Moderate

Intervention not reported

The intervention may leads to lower HIT in people undergoing major surgical procedures (low certainty).

• Unfractionated heparin versus low molecular weight heparins for avoiding heparin‐induced thrombocytopenia in… 2017 · Cochrane Headline outcomes only
  RR 0.22 [0.06, 0.75]
  2 studies · 586 participants
  Low

Intervention not reported

The intervention may leads to lower HIT complicated by venous thromboembolism (low certainty).

• Unfractionated heparin versus low molecular weight heparins for avoiding heparin‐induced thrombocytopenia in… 2017 · Cochrane Headline outcomes only
  RR 0.22 [0.06, 0.84]
  3 studies · 1398 participants
  Low

Low molecular weight heparin vs placebo

It is very uncertain whether LMWH changes endoscopic remission compared with placebo (very low certainty).

• Unfractionated or low‐molecular weight heparin for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 1.34 [0.66, 2.72]
  1 study · 141 participants
  Very low

LMWH + standard therapy vs usual care

It is very uncertain whether LMWH + standard therapy changes clinical remission compared with standard therapy (very low certainty).

• Unfractionated or low‐molecular weight heparin for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.8 [0.32, 2.04]
  1 study · 34 participants
  Very low

LMWH + standard therapy vs usual care

It is very uncertain whether LMWH + standard therapy changes clinical improvement compared with standard therapy (very low certainty).

• Unfractionated or low‐molecular weight heparin for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 1.13 [0.83, 1.53]
  1 study · 34 participants
  Very low

LMWH + standard therapy vs usual care

It is very uncertain whether LMWH + standard therapy changes endoscopic remission compared with standard therapy (very low certainty).

• Unfractionated or low‐molecular weight heparin for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.8 [0.32, 2.04]
  1 study · 34 participants
  Very low

LMWH + standard therapy vs usual care

It is very uncertain whether LMWH + standard therapy changes endoscopic improvement compared with standard therapy (very low certainty).

• Unfractionated or low‐molecular weight heparin for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 1.13 [0.69, 1.85]
  1 study · 34 participants
  Very low

UFH vs corticosteroids

It is very uncertain whether UFH changes clinical improvement compared with corticosteroids (very low certainty).

• Unfractionated or low‐molecular weight heparin for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.06 [0, 0.88]
  1 study · 25 participants
  Very low

Tinzaparin vs placebo

• Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 253 participants
  Very low

Dalteparin vs placebo

• Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 35 participants
  Very low

Dalteparin vs placebo

The review found no eligible studies for this question.

• Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Dalteparin vs placebo

The review found no eligible studies for this question.

• Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Dalteparin vs placebo

The review found no eligible studies for this question.

• Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Dalteparin vs placebo

The review found no eligible studies for this question.

• Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Dalteparin vs placebo

The review found no eligible studies for this question.

• Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Dalteparin vs placebo

The review found no eligible studies for this question.

• Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found